From: Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases
AR (n = 236) | CG (n = 1545) | P value | AR (n = 236) | CG (n = 1545) | P value | |
---|---|---|---|---|---|---|
No symptoms | 114 (48.3) | 968 (62.7) | < 0.001 | 141 (59.7) | 1166 (75.5) | < 0.001 |
Local reaction | 75 (31.8) | 309 (20.0) | < 0.001 | 69 (29.2) | 253 (16.4) | < 0.001 |
Pain | 71 (30.1) | 292 (18.9) | < 0.001 | 64 (27.1) | 232 (15.0) | < 0.001 |
Redness | 2 (0.8) | 8 (0.5) | 0.870 | 3 (1.3) | 11 (0.7) | 0.610 |
Swelling | 8 (3.4) | 26 (1.7) | 0.126 | 9 (3.8) | 27 (1.7) | 0.064 |
Pruritus | 0 | 4 (0.3) | 1.000 | 0 | 3 (0.2) | 1.000 |
Malaise | 0 | 2 (0.1) | 1.000 | 0 | 1 (0.1) | 1.000 |
Systemic reactions | 72 (30.5) | 354 (22.9) | 0.011 | 42 (17.8) | 172 (11.1) | 0.003 |
Fever | 6 (2.5) | 28 (1.8) | 0.611 | 5 (2.1) | 14 (0.9) | 0.177 |
Chills | 4 (1.7) | 8 (0.5) | 0.103 | 0 | 5 (0.3) | 1.000 |
Fatigue | 40 (16.9) | 151 (9.8) | < 0.001 | 21 (8.9) | 77 (5.0) | 0.014 |
Headache | 5 (2.1) | 17 (1.1) | 0.316 | 3 (1.3) | 5 (0.3) | 0.132 |
Vertigo | 12 (5.1) | 50 (3.2) | 0.149 | 6 (2.5) | 25 (1.6) | 0.312 |
Somnolence | 3 (1.3) | 25 (1.6) | 0.906 | 3 (1.3) | 10 (0.6) | 0.523 |
Vomiting | 4 (1.7) | 14 (0.9) | 0.436 | 1 (0.4) | 4 (0.3) | 0.509 |
Diarrhea | 10 (4.2) | 24 (1.6) | 0.011 | 2 (0.8) | 14 (0.9) | 0.778 |
Abdominal pain | 1 (0.4) | 6 (0.4) | 1.000 | 0 | 3 (0.2) | 1.000 |
Stuffy nose | 3 (1.3) | 16 (1.0) | 0.990 | 1 (0.4) | 10 (0.6) | 0.970 |
Sore throat | 6 (2.5) | 27 (1.7) | 0.559 | 3 (1.3) | 16 (1.0) | 0.990 |
Cough | 3 (1.3) | 14 (0.9) | 0.859 | 2 (0.8) | 9 (0.6) | 0.970 |
Chest pain | 0 | 1 (0.1) | 1.000 | 0 | 0 | 1.000 |
Cardiopalmus | 1 (0.4) | 3 (0.2) | 0.434 | 1 (0.4) | 3 (0.2) | 0.434 |
New or worsened muscle pain | 6 (2.5) | 15 (1.0) | 0.079 | 4 (1.7) | 13 (0.8) | 0.370 |
New or worsened joint pain | 0 | 3 (0.2) | 1.000 | 1 (0.4) | 4 (0.3) | 0.509 |
Skin rash | 4 (1.7) | 19 (1.2) | 0.780 | 2 (0.8) | 7 (0.5) | 0.762 |